Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]
Article information
Clin Mol Hepatol. 2025;31(2):669-670
Publication date (electronic) : 2025 February 27
doi :
https://doi.org/10.3350/cmh.2024.0333e
In the original publication of this paper, the second graph in Figure 4B was erroneously identical with fourth graph in Figure 4B and correct version is provided below. We apologize for any inconvenience that may have been caused.
The original article has been corrected as of 27th February 2025.
Before correction
Figure 4B.
After correction
Figure 4B.
Article information Continued
Copyright © 2025 by The Korean Association for the Study of the Liver